Target Healthcare REIT (LSE:THRL) Research & Development: £0.00 Mil (TTM As of Dec. 2025)


LSE:THRL Target Healthcare REIT PLC LSE:THRL
32 GF Score
Price £1.04
GF Value £0.89
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Target Healthcare REIT Research & Development?

Target Healthcare REIT LSE:THRL -1.14% 32 Research & Development is £0.00 Mil as of Dec. 2025. GuruFocus rates LSE:THRL with a GF Score™ of 32/100 and a GF Value™ of £0.89 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Target Healthcare REIT's Research & Development for the six months ended in Dec. 2025 was £0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was £0.00 Mil.

Target Healthcare REIT  (LSE:THRL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Target Healthcare REIT Research & Development Related Terms

Target Healthcare REIT Research & Development Historical Data

* Premium members only.

The historical data trend for Target Healthcare REIT's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Target Healthcare REIT Research & Development Chart

Target Healthcare REIT Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Target Healthcare REIT Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:THRL
32GF Score
Target Healthcare REIT PLC LSE:THRL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Target Healthcare REIT Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £0.00 Mil mean?
Target Healthcare REIT (LSE:THRL) has a Research & Development of £0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Target Healthcare REIT and its competitors.
Is Target Healthcare REIT's Research & Development too high?
Target Healthcare REIT's current Research & Development is £0.00 Mil. Overall, Target Healthcare REIT has a GF Score™ of 32/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Target Healthcare REIT's Research & Development compare to WELL and VTR?
Target Healthcare REIT's Research & Development of £0.00 Mil can be compared against companies in the REITs industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a REITs company?
A good Research & Development depends on the REITs industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Target Healthcare REIT and its competitors. Target Healthcare REIT's current Research & Development is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Target Healthcare REIT stock overvalued right now?
Based on GuruFocus' analysis, Target Healthcare REIT (LSE:THRL) is currently considered Modestly Overvalued. The stock's GF Value™ is £0.89, compared to a current price of £1.04 — trading 16.9% above its estimated fair value. The current Research & Development is £0.00 Mil. Target Healthcare REIT's overall GF Score™ is 32/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Target Healthcare REIT (LSE:THRL), the current Research & Development is £0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Target Healthcare REIT (LSE:THRL) Overvalued in 2026?

Based on GuruFocus' analysis, Target Healthcare REIT stock appears to be overvalued. The current stock price of £1.04 is trading 16.9% above its estimated GF Value™ of £0.89. GuruFocus considers Target Healthcare REIT to be Modestly Overvalued.

Key valuation signals for LSE:THRL:

  • Research & Development: £0.00 Mil
  • GF Value™: £0.89 vs. price of £1.04 (16.9% above fair value)
  • GF Score™: 32/100 with 7 warning signs

No single metric tells the full story. See the LSE:THRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Target Healthcare REIT Business Description

Industry Real EstateREITs
Address 69 Old Broad Street, Level 4, Dashwood House, London, GBR, EC2M 1QS
Target Healthcare REIT PLC is an investment company that acts as a long-term investor in care homes in the United Kingdom. The investment objective of the company is to provide shareholders with an attractive level of income together with the potential for capital and income growth from investing in a diversified portfolio of freehold and long-leasehold care homes, which are let to care home operators, and other healthcare assets in the United Kingdom.
32GF Score

Get the complete analysis for LSE:THRL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£1.04
Price
£0.89
GF Value